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Abstract 
Objectives. Visual hallucinations (VH) are common in Lewy body disease (LBD), 
and have been associated with cognitive and structural brain alterations. 
ǀŝĚĞŶĐĞƐŽĨĂƌĐŽŶĐĞƌŶƐŵĂŝŶůǇWĂƌŬŝŶƐŽŶ ?ƐĚŝƐĞĂƐĞ ?W ? ?ďƵƚůŝƚƚůĞŝƐŬŶŽǁŶ
about symptom-specific pathophysiological mechanisms across the LBD 
spectrum, especially related to the presence of dementia. The aim of the 
present pilot study was to investigate the neuroanatomical, and 
neuropsychological characteristics related to VH in two forms of LBD, namely 
dementia with Lewy bodies (DLB) and PD without dementia. Methods. Whole 
brain voxel-based morphometry (VBM) analyses on 3D MRI acquired structural 
brain scans, and neuropsychological testing were performed on 28 clinically 
diagnosed DLB (11 with VH, 17 NVH), and 24 PD (9 with VH, and 15 NVH) 
patients. In order to assess differences in grey matter (GM) regional volumes, 
and cognitive performance, hallucinating patients for each group were 
compared with corresponding non-hallucinating ones. Results. DLB patients 
with VH presented significantly worse visual attention deficits compared to 
those without, which persisted even when controlling for visual perception. 
Whole brain VBM analysis revealed decreased GM volume in DLB with VH in the 
right superior and medial frontal gyri, putamen, caudate nucleus and insula. 
Subcortical regional volumes were also significantly associated with visual 
attention performance. Hallucinating PD patients, instead, presented more 
severe executive dysfunction, but VBM showed no volumetric differences 
between the two PD subgroups. Post hoc region of interest analyses revealed 
striatal GM loss in PD with VH. Conclusion. Frontal and striatal GM atrophy may 
contribute to the emergence of VH in DLB, which may be fostered by the more 
severe attention deficits. Striatal GM loss and executive dysfunction, instead, 
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appeared to underlie VH in PD without dementia. 
<ĞǇǁŽƌĚƐ PǀŝƐƵĂůŚĂůůƵĐŝŶĂƚŝŽŶƐ ?>ĞǁǇďŽĚǇ ?WĂƌŬŝŶƐŽŶ ?ƐĚŝƐĞĂƐĞ ?ĚĞŵĞŶƚŝĂǁŝƚŚ
Lewy bodies; MRI; VBM; grey matter; frontal; striatum; attention; executive 
dysfunction  
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1.0 Introduction 
The main pathological feature of Lewy body disease (LBD) is the inclusion of pathologic ɲ-
synuclein aggregates called Lewy bodies (LBs) [1,2]. Dementia with Lewy bodies (DLB) and 
WĂƌŬŝŶƐŽŶ ?ƐĚŝƐĞĂƐĞ ?W ?ĂƌĞĐůŝŶŝĐĂůŵĂŶŝĨĞƐƚĂƚŝŽŶƐŽĨ>ƉĂƚŚŽůŽŐǇ ?ĂŶĚƐŚĂƌĞĐůŝŶŝĐĂůĨĞĂƚƵƌĞƐ ?
among which visual hallucinations (VH). VH are among the core characteristics for a diagnosis 
of DLB, and they have been identified as the more specific clinical feature differentiating DLB 
ĨƌŽŵůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞ ? ?ĂƚĞĂƌůǇƐƚĂŐĞƐ[3,4]. VH may be considered a marker of LB 
pathology, being a strong predictor of LBs accumulation [4-6]. 
VH are often present since the early stages of DLB, and are considered an important hallmark 
of the disorder [3]. On the other hand, they tend to occur later in the progression of PD, with 
longer disease duration identified as independent predictor of VH in this disease [7,8]. VH tend 
to be more frequent, complex and severe in patients with DLB and PD-dementia (PDD), who 
are often unaware of the unreal nature of their sensory experience [6].  
Despite the high rate of VH in DLB, their cognitive and neuroanatomical correlates in this 
disorder have not been studied extensively, while more evidence is available for PD. Collerton 
et al. [9] suggested that VH generate from a combined deficit in top-down and bottom-up 
processes, respectively in visual attention and visual perception. Visuoperceptive and 
visuoconstructive deficits have been found in patients with VH by several neuropsychological 
studies in PD [10-17], and some in DLB and PDD [18,19]. On the other hand, contrasting 
findings are available for visual attention, some showing poorer performance in PD [11,13,20] 
and DLB [21] with VH, but not others [22,23]. To our knowledge, no study so far has taken into 
account the interaction between these deficits, investigating whether there is an interplay 
between disruptions in these two aspects of cognition in LBD patients with VH.  
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Neuroimaging techniques have been used to explore in vivo functional and structural brain 
features related to VH in LBD [24]. Among structural anatomical features, grey matter (GM) 
loss in occipito-temporal regions represents one of the most consistent findings characterising 
PD with VH, while the scarce evidence available for DLB suggests a greater involvement of 
frontal areas [25-29]. Some findings have also been confirmed by FDG-PET and SPECT studies 
that identified reduced glucose metabolism/perfusion in occipito-temporal, occipital, and 
parietal regions in hallucinating LBD patients with and without dementia, but inconsistencies 
have been reported about frontal hypometabolism [22-24,30-32]. Neuropathological studies, 
however, have reported high concentration of LBs in hallucinating patients, mainly in temporal 
and frontal regions [8,33,34]. In this context, VH may generate from concomitant impairments 
of large-scale functional networks for visual attention, with frontal atrophy as structural 
marker, and dysfunctional visual processes, underlined by occipito-temporal atrophy and 
hypometabolism [24]. However, due to the limited amount of studies in the field, this 
hypothesis needs further investigation. Moreover, VH in LB dementia have been investigated 
by a few studies only, making difficult to infer if and how neuroanatomical and neurocognitive 
features associated with VH differ across the LBD spectrum, especially relative to the presence 
of dementia. Despite the relationship between VH and cognitive impairment, the association 
between specific cognitive domains and brain regions and networks altered in LBD patients 
with VH is still a poorly investigated area [24].  
Top-down modulation refers to the goal-based neural modulation of cortical sensory areas to 
prioritise the processing of task-relevant information [35]. The neural mechanism underlying 
the top-down control of spatial attention has been shown to rely on a fronto-parietal network 
of brain regions, directly interconnected to each other, and indirectly through subcortical hubs 
located in the striatum, and the pulvinar nucleus of the thalamus [35,36]. The role that these 
subcortical nuclei play in top-down attentional control suggests that their alteration may also 
constitute a vulnerability to VH.  
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In an attempt to reconcile findings in the current literature, the present pilot study aimed at 
investigating the cognitive and anatomical brain features related to VH in separate samples of 
patients with DLB and PD without dementia. Firstly, we explored whether there was an 
interplay between deficits in top-down (visual attention) and bottom-up (visual perception) 
mechanisms in the expression of VH. Then, a whole brain VBM approach was used to detect 
brain volumetric differences between patients with and without VH (VH versus NVH) within 
each diagnostic group, and correlational analyses were run to identify regional brain volumes 
associated with visual attention and visual perception/construction. We expected GM loss in 
fronto-parietal regions and subcortical nuclei (pulvinar and striatum), sustaining attention 
deficits, and occipito-temporal areas, related to impaired perception abilities.   
2.0 Materials and Methods 
2.1 Sample 
The present study involved 28 clinically diagnosed patients with DLB (11 VH and 17 NVH), and 
24 patients with idiopathic PD1 (9 VH, and 15 NVH). In order to assess further structural brain 
abnormalities in PD with and without VH, 15 healthy controls were also included in the 
neuroimaging section of the study. This study was approved by the ethical committee of Padua 
Teaching Hospital, Padua, Italy, where data for the DLB group were collected and by the 
Institutional Review Board of the IRCCS Fondazione Ospedale San Camillo, Venice, Italy, where 
data for the PD group were collected. Informed consent was obtained from each participant.   
Clinical diagnosis of DLB was based on the consensus criteria proposed by the DLB consortium 
[3]. DLB patients were included in the study if they presented mild to moderate cognitive 
                                                          
1
 Data for the PD sample were collected while  Angelo Antonini was employed by the IRCCS 
Fomdazione Ospedale San Camillo, Venice, Italy 
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decline, as assessed using a Mini-Mental State Examination (MMSE) test score cut-off of 18 or 
above. None of the patients presented severe cerebrovascular disease, assessed by brain CT or 
MRI scan, history of psychiatric disorders, and severe eye pathology impairing visual acuity 
(cataract, glaucoma, macular degeneration). Specifically, a neuro-ophthalmologic assessment 
was carried out including external inspection of the eyes, pupil reactions, penlight reflex, 
measure of near vision acuity, ocular movements and estimation of the visual field by 
confrontation test. Visual acuity and visual field were normal (or corrected to normal for visual 
acuity) in all patients. Medications used included: cholinesterase inhibitors, benzodiazepines, 
antidepressants. Neuroleptic drugs were taken by 45% of patients with VH and by one without 
VH. Only patients on a stable dose of cholinesterase inhibitors and/or levodopa for at least 3 
months were included in the analyses.  
Diagnosis of PD was based on the UK PD Brain Bank Criteria [37]. Patients with mild/moderate 
and severe cognitive decline were excluded from the study, using a MMSE cut-off of 24. 
According to the Hoehn and Yahr (H&Y) staging system, all patients were in the mild stage of 
the disease (between stage 1 and 3) [38]. Patients had no previous history of psychiatric or 
other neurological disorders, except for one patient with VH who had a history of depressive 
symptoms. All patients in this group also had a neuro-ophthalmologic assessment as describef 
above.  Visual acuity and visual field were normal (or corrected to normal for visual acuity) in 
all patients. All PD patients were treated with levodopa and 75% of them with dopamine 
agonists. Besides levodopa, dopaminergic therapy included pramipexole (n=13), pergolide 
(n=1) and ropinirole (n=4). Levodopa equivalent dose (LED) in mg/d was calculated for each 
antiparkinsonian medication as described by Moller et al. [39]. Other medications used were: 
monoamine oxidase inhibitors, antidepressants and benzodiazepines.  
The healthy control sample included 15 participants with no previous history of psychiatric or 
neurological diseases. 
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All participants underwent a comprehensive neurological and clinical examination. In DLB, the 
following ǁĞƌĞĂĚŵŝŶŝƐƚĞƌĞĚ PhŶŝĨŝĞĚWĂƌŬŝŶƐŽŶ ?ƐŝƐĞĂƐĞZĂƚŝŶŐ^ĐĂůĞŵŽƚŽƌƐĐŽƌĞƐƵďƐĞĐƚŝŽŶ
III (UPDRS-III) [40], Mayo Fluctuations Questionnaire [41], and the Mayo Sleep Questionnaire 
[42]. Disease severity for patients with PD was measured using the Hoehn and Yahr (H&Y) 
scale [38]. Behavioural disorders were evaluated with the Neuropsychiatric Inventory (NPI) 
questionnaire [43]. The NPI subsection for hallucinations was used to assess the presence, 
severity and frequency of VH.  Only patients with recurrent, complex VH were included in the 
study. The sensory modality of hallucinatory phenomena was ascertained with a qualitative 
ĂƐƐĞƐƐŵĞŶƚƐŽĨƌĞƉŽƌƚĞĚƉĂƚŝĞŶƚƐ ?ĞǆƉĞƌŝĞŶĐĞƐ ? 
2.2 Neuropsychological assessment 
Global cognitive functioning was evaluated with the MMSE [44]. Each patient underwent a 
comprehensive neuropsychological assessment using the Italian version of each test. Visual 
attention deficits were evaluated with the digit cancellation test [45], and the Trail Making 
Test part A (TMT-A) [46]. Assessment of visuoperceptive/visuo-spatial and visuoconstructive 
abilities was performed with the Visual and Object Space Perception (VOSP) Battery [46,47], 
and Rey-Osterrieth Complex Figure (ROCF) [48], respectively.  
An extensive battery of neuropsychological tests was used for screening for cognitive 
impairment and to ensure that patients with and without VH were comparable in severity.  
This battery included: Frontal Assessment Battery (FAB) [49,50], letter fluency [46], and a short 
version of the Stroop colour-word test [51] test for executive functioning; prose memory test 
[52] and Rey Auditory Verbal Learning Test (RAVLT) [46] for verbal long-term memory; clock 
drawing test [53] for visuospatial and executive abilities; digit span forward and backward 
[46,54] for short-term and working memory.  
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The following tests were administered to DLB patients only: digit cancellation, clock drawing 
test and VOSP; while the following just to PD patients: RAVLT, Stroop test and FAB. Scores for 
all the remaining tests were available for both groups.  
2.3 MRI acquisition 
Three dimensional T1 weighted structural scans were all acquired with the same MRI scanner, 
a 1.5 Tesla Philips Achieva running the same software release. The sequence used was a Turbo 
Field Echo and acquisition was sagittal.  The following acquisition parameters were applied: 
TR=7.4 ms, TE=3.4 ms, field of view (FOV): 220 mm for DLB and 230 for PD, flip angle: 8°, 160 
slices, voxel dimension 1.04x1.04x0.66 mm, gap 0.6. 
2.4 VBM pre-processing 
Whole brain VBM was carried out using the Statistical Parametric Mapping (SPM) 12 software 
(Wellcome Centre for Human Neuroimaging, London, UK), running on MATLAB R2014a, 
version 8.3 (The MathWorks, Icn, Natick, Massachussetts), including pre-processing and 
statistical analyses. First, structural MRI data were manually reoriented to the Anterior 
Commissure-Posterior Commissure line, segmented into GM, white matter (WM) and 
cerebrospinal fluid (CSF), spatially normalised to MNI space, and modulated to preserve 
absolute volumes. Images were, then, smoothed using a FWHM 8mm isotropic Gaussian 
kernel. Total GM, WM, and CSF volumes were determined using the MATLAB  “get_totals ? 
script (http://www0.cs.ucl.ac.uk/staff/g.ridgway/vbm/get_totals.m) from each image in native 
space. Total intracranial volume (TIV) was calculated for each patient by summing GM, WM 
and CSF total volumes.  
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2.5 Statistical analyses 
IBM SPSS Statistics 22 was used to assess differences in demographic, clinical and 
neuropsychological characteristics, and total brain volumes within each diagnostic group. For 
the DLB group, differences between patients with and without VH were investigated using the 
following statistics: independent sample t-test and Mann-Whitney U test for normally and 
non-normally distributed numerical variables ƌĞƐƉĞĐƚŝǀĞůǇ ?&ŝƐŚĞƌ ?ƐǆĂĐƚdĞƐƚ was used for 
categorical variables. Differences in demographics between PD subgroups and healthy controls 
were assessed using one-way ANOVA and Kruskal-Wallis tests for normally and non-normally 
distributed numerical variables respectively. Categorical variables were analysed with the 
Pearson Chi-Square test. Statistical analyses of neuropsychological tests were conducted as 
detailed above for the DLB group. Bonferroni correction was applied to account for multiple 
comparisons, by which statistical significance ŝƐƌĞĂĐŚĞĚǁŝƚŚĂƉǀĂůƵĞAMɲ ?Ŷ ?ǁŚĞƌĞɲŝƐĞƋƵĂů
to the p value for each comparison (p=0.05) and n the number of comparisons. Corrections 
were applied independently to the screening set and to the experimental set. For DLB group 
comparisons, significance level was lowered to p = 0.0033 for the screening set and to p =  
0.0125 for the experimental set.  For the PD group comparisons, significance level was lowered 
to p = 0.0055 for the screening set and to p =  0.025 for the experimental set.   Non-parametric 
correlations (Spearman's rho test) were run between VH severity and frequency, and attention 
and visuospatial tests within each diagnostic group.  
A general linear model (GLM) was used to assess attentional deficits in patients with VH 
controlling for visuoperceptive/visuoconstructive deficits, separately for each patient group. 
Specifically, ANCOVA analyses were performed by entering performance on a relevant 
attention test as the dependent variable, performance on a visuoperceptive/visuoconstructive 
test as a covariate of no interest, and the presence of VH as a fixed factor. Moreover, in order 
to investigate changes in visuoperceptive/visuoconstructive deficits accounting for visual 
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attention deficits, an ANCOVA design was used with a visuoperceptive/visuoconstructive test 
as the dependent variable, an attention test as covariate of no interest, and the presence of 
VH as a fixed factor. 
In the VBM analyses, GLM with TIV and age as covariates of no interest was used to determine 
differences between groups in GM and WM volumes. TIV was included in the model to 
account for individual global differences while investigating regional changes. Within each 
diagnostic group, the following contrasts were performed: VH < NVH and VH > NVH. Each PD 
subgroup was further compared to a group of healthy controls. The same procedure was 
performed for whole brain correlation analyses, undertaken to assess the association between 
regional GM volumes, cognitive functions and VH severity and frequency.  
To exclude voxels outside the brain, relative threshold masking of 0.2 and 0.8 were applied for 
GM and WM analyses, respectively. Significance level was set at p<0.001 uncorrected for 
multiple comparisons (set-level). A cluster-level threshold of p<0.05 FWE (family wise error) 
corrected for multiple comparisons was chosen to report significant results in all the analyses.   
Montreal Neurological Institute (MNI) coordinates were converted into Talairach coordinates 
using GingerALE, version 2.3.6 (available online at http://www.brainmap.org/ale/). Then, the 
Talairach Client, version 2.4.3 (available online at http://www.talairach.org/client.html) was 
used to determine brain region labels for each significant cluster. White matter regions were 
determined using the following atlases: the JHU white-matter tractography and ICBM-DTI-81 
white-matter labels atlases, available on FSL [55-57].     
2.6 Post hoc region of interest analyses 
To assess our a priori hypothesis of an involvement of the pulvinar and the striatum in the 
mechanisms underlying VH, ROIs were placed post-hoc in the left and right pulvinar, putamen 
and caudate nucleus, and other control regions, namely the left and right lateral geniculate 
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body, hippocampus and primary motor cortex. The lateral geniculate body was chosen as 
control nucleus of the thalamus, the hippocampus as control region involved in cognitive 
processing, and the primary motor cortex as control region not involved in high cognitive 
functioning. ROIs were created with the WFU PickAtlas toolbox, version 3.0.5 [58,59], 
specifically using the Brodmann Area atlas based on the Talairach Daemon (TD) database 
[60,61]. In order to investigate whether the VBM results were associated with cognitive 
performance, ROI masks were generated post hoc based on the significant clusters from the 
VBM analysis. Further post hoc analyses were undertaken within the PD sample to assess 
group differences in line with our a priori hypotheses. The ROIs were chosen in frontal, 
parietal, occipital and occipito-temporal regions. Specifically, differences between PD patients 
with and without VH were investigated in the following ROIs: left and right frontal eye field (BA 
8), superior parietal lobule (BA 7), primary visual cortex, secondary visual cortex (BA 18), visual 
associative cortex (BA 19), inferior temporal area (BA 20), and occipitotemporal area (BA 37). 
The frontal eye field and the superior parietal lobule were chosen for their role in goal-
directed visual attention [36,62,63]. On the other hand, the formation of objects visual 
representations is sustained by a ventral visual pathway, identified in an occipito-temporal 
network of regions lying between primary visual cortices and other specialised areas involved 
in memory and learning, forming representations comprising stable elements of visual 
information [64]. Key regions in this process include primary and associative visual cortices, 
occipito-temporal cortex, and inferior temporal areas [64,65].  
GM volumes in these regions were extracted from each patient ?Ɛ smoothed, segmented, 
normalised, and modulated image by using the MarsBar toolbox for SPM 
(http://marsbar.sourceforge.net). Then, volumetric differences between hallucinating and 
non-hallucinating patients within each diagnostic group were, then, assessed performing 
ANCOVA analyses with TIV and age as covariates of no interest. Volumes were also correlated 
with the scores achieved on relevant cognitive tests using the same covariates (partial 
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correlations). Non-parametric correlations (Spearman's rho) were also performed to 
investigate the relationship with VH severity and frequency.  
3.0 Results 
3.1 Demographic and clinical features 
Details and statistical tests on demographic, clinical, volumetric characteristics are reported in 
Table 1 and Table 2 for DLB and PD patients, respectively. The two subgroups of DLB patients 
did not significantly differ in age, gender, years of education, age of onset, duration of disease, 
presence of cognitive fluctuations, and UPDRS scores. Patients with DLB and VH presented 
higher percentage of RBD symptoms and had higher NPI scores. PD patients with and without 
VH and healthy controls did not differ significantly in age, gender and years of education. No 
differences were detected between PD subgroups in disease duration, H&Y scores, presence of 
sleep disturbances and LED. The most common sleep disturbance was repeated awakenings. 
Only one patient with VH presented RBD. PD patients with VH had higher NPI total scores; 
differences remained significant also after subtracting the NPI hallucination subscore.  
- Insert Table 1 and Table 2 about here - 
3.2 Neuropsychological findings 
3.2.1 Dementia with Lewy bodies 
A summary of scores on the screening tests is given in Table S1. Patients with VH had similar 
performance in global cognitive functioning, compared with patients without, as assessed with 
the MMSE (p=0.07).  
To test the hypothesis of an involvement of visual attention and visual 
perception/construction in the development of VH, the following experimental tests were 
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taken into account: digit cancellation test, TMT-A, VOSP subtest silhouettes, copy of the Rey 
figure. The results from the comparison between patients with and without VH in these tests 
are reported in Table 3. Patients with VH had poorer performance in the digit cancellation test 
(p=0.01, Figure 1). Differences in the digit cancellation test were marginally significant when 
controlling for global cognitive functioning assessed with the MMSE (ANCOVA analysis, 
p=0.05). Even though statistically not significant, patients with VH presented worst 
performance on the copy of the Rey figure, with 4 patients out of 9 scoring 0 (as opposed to 1 
patients out of 14 in the non-halluciŶĂƚŝŶŐŐƌŽƵƉ ? ?&ŝƐŚĞƌ ?ƐǆĂĐƚdĞƐƚ ?ƉA? ? ? ? ? ? ?ŝĨĨĞƌĞŶĐĞŝŶ
the TMT-A showed a trend towards significance, even when controlling for MMSE (ANCOVA 
analysis, p=0.05).  
- Insert Table 3 and Figure 1 about here - 
Differences in the digit cancellation test persisted even when controlling for the VOSP subtest 
silhouettes (ANCOVA analysis, p=0.04), and the copy of the Rey figure (ANCOVA analysis, 
p=0.03). No differences were found in VOSP silhouettes (ANCOVA analysis, p=0.56) and copy of 
the Rey figure (ANCOVA analysis, p=0.71) when controlling for digit cancellation scores.  
Non-parametric correlation analyses (Spearman's rho test) showed no significant association 
between severity and frequency of VH and performance on the digit cancellation, VOSP 
silhouettes, and copy of the Rey figure. Scores on the Rey figure copy was significantly 
correlated with VH frequency (p=0.03). When considering the NPI hallucination score 
(frequency x severity), performance on the TMT-A (p=0.003) and Rey figure copy (p=0.03) was 
found to correlate significantly, but not the digit cancellation test and the VOSP silhouettes.  
Results for the other neuropsychological tests are reported in supplementary materials.  
Briefly, VH patients presented greater impairment compared with NVH only in the digit span 
backward (p=0.04), and delayed recall of Rey figure (p=0.03). None of these significant 
differences survived correction for multiple comparisons (p<0.003). Moreover, when 
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accounting for MMSE scores, differences in the digit span backward (ANCOVA analysis, p=0.23) 
and Rey figure delayed recall (ANCOVA analysis, p=0.16) were no longer significant. No 
significant differences were found in the following tests: digit span forward, prose memory 
(immediate and delayed recall), letter fluency, clock drawing, copy of the Rey figure, and all 
the VOSP subtests. 
3.2.2 ParNLQVRQ¶VGLVHDVH 
A summary of scores on the screening tests is given in Table S2. PD patients with and without 
VH did not differ significantly in global cognitive performance (MMSE, Post-hoc ƵŶŶ ?Ɛ
pairwise test, p=0.52), but MMSE scores were significantly lower than controls (Post-hoc 
ƵŶŶ ?ƐƉĂŝƌǁŝƐĞƚĞƐƚ, VH vs. controls: p=0.001; NVH vs. controls: p=0.03).  
No differences between patients with and without VH were detected in the TMT-A and Rey 
figure copy. Results are reported in Table 4. ANCOVA analyses revealed no significant 
differences in the TMT-A controlling for the copy of the Rey figure (p=0.49); and no differences 
in the Rey figure copy controlling for the TMT-A (p=0.76). Non-parametric correlations 
(Spearman's rho) showed no significant association between TMT-A and copy of the Rey 
figure, and VH severity, frequency, and NPI hallucination score.  
- Insert Table 4 about here - 
Patients with VH presented greater impairment compared with those without in the RAVLT 
immediate recall (p=0.03), and FAB (p=0.006). Differences in scores on the letter fluency test 
were marginally significant (p=0.05) between VH and NVH groups. None of the differences 
survived correction for multiple comparisons (p<0.006). No significant differences were found 
in the following tests: digit span forward and backward, RAVLT delayed recall, Rey figure recall, 
Stroop tests (seconds and errors). In the comparison between patients with and without VH, 
differences in the FAB remained significant (ANCOVA analysis, p=0.02) after controlling for the 
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NPI total score minus the NPI hallucination subscore, but those in RAVLT immediate recall 
(ANCOVA analysis, p=0.08), and letter fluency (ANCOVA analysis, p=0.31) did not. Post-hoc 
correlation analyses on the tests where significant differences between VH and NVH patients 
were present revealed significant correlations (Spearman's rho) between the NPI hallucination 
score and performance on the FAB (p=0.001), and RAVLT immediate recall (p=0.03), but not on 
letter fluency (p=0.08). The total NPI score minus NPI hallucination also correlated with 
performance on the FAB (p=0.02), and letter fluency (p=0.03), but not on the RAVLT (p=0.15).  
3.3 Whole brain VBM findings 
3.3.1 Dementia with Lewy bodies 
Reduced GM in DLB patients with VH in comparison with those without was found in three 
clusters located in frontal and subcortical areas. Specifically, peak coordinates were shown in 
the right superior frontal gyrus, putamen and medial frontal gyrus, with TIV and age included 
as covariate of no interest (Table 5 and Figure 2). All clusters were significant at a cluster-level 
threshold of p<0.05 FWE corrected for multiple comparisons. When the analysis was repeated 
including MMSE as covariate of no interest (in addition to TIV and age), only one cluster 
survived cluster-level correction for multiple comparisons. Peak coordinates were found in the 
right superior frontal gyrus, BA 10 (MNI coordinates: x=9, y=62, z=-12; cluster size: k=703 
voxels; T score: 6.09; Z score: 4.65; p=0.01). Sub-peaks were located in the right superior 
frontal (BA 10; MNI coordinates: x=21, y=62, z=4; T score: 5.01; Z score: 4.08) and middle 
frontal gyri (MNI coordinates: x=34, y=54, z=-9; T score: 4.74; Z score: 3.92).  
- Insert Table 5 and Figure 2 about here - 
Whole brain analysis on WM revealed one cluster of reduced volume in the forceps 
minor/genu of corpus callosum (Table 5), which disappeared when adding MMSE scores in the 
model as covariate of no interest.  
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Whole brain correlation analyses showed positive associations between a) the digit 
cancellation test scores and the right putamen and left caudate nucleus volumes, and b) the 
VOSP silhouettes subtest scores and the right inferior temporal gyrus volume (Table 5 and 
Figure 3). No regions of GM volume were associated with scores on the copy of the Rey figure, 
VH severity and frequency.  
- Insert Figure 3 about here - 
3.3.2 3DUNLQVRQ¶VGLVHDVH 
The same analyses in PD patients yielded no between group differences in regional GM and 
WM volumes using a cluster-level threshold of p<0.05 FWE corrected for multiple 
comparisons. No differences were found between each PD subgroup and a group of healthy 
controls. The analyses were repeated with no covariates of no interest, but no results reached 
statistical significance. 
3.4 Post hoc region of interest analyses 
3.4.1 Dementia with Lewy bodies 
ROI analyses reported statistically significant differences in the left (p=0.0004) and right 
caudate nucleus (p=0.002), left putamen (p=0.04), left (p=0.02) and right hippocampus 
(p=0.01), using an ANCOVA design with TIV and age as covariates of no interest. Adding MMSE 
as covariate to the design, the left (p=0.002) and right caudate nucleus (p=0.02), the left 
putamen (p=0.04), the left hippocampus remained significant (p=0.03), while the right was 
only marginally significant (p=0.05). The only differences that survived correction for multiple 
comparisons (p<0.004) were in the left and right caudate nucleus. No significant differences 
were found in the other ROIs.  
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In order to investigate whether regions of reduced GM were associated with cognitive deficits, 
volumes within the clusters that were found to be significantly different between DLB 
subgroups were extracted and correlated with performance on the digit cancellation test and 
the TMT-A (assessing visual attention) within the whole DLB group. Partial correlational 
analyses (controlling for TIV and age) showed a statistically significant positive association 
between scores on the digit cancellation and the subcortical ROIs (within the putamen, insula 
and caudate nucleus; n=26, R=0.58, p=0.003; Figure 4). No other significant correlation was 
found with the ROIs based on the VBM results. Partial correlations were also run between the 
digit cancellation and TMT-A scores and the left and right pulvinar, in line with our hypothesis, 
which showed no significant results. None of the ROIs was associated with severity and 
frequency of VH (Spearman's rho correlations).  
- Insert Figure 4 about here - 
3.4.2 3DUNLQVRQ¶VGLVHDVH 
ROI analyses were performed to investigate differences between patients with and without VH 
in PD, based on a priori hypotheses (covariates: TIV, age). Even though not surviving correction 
for multiple comparisons (p<0.002), significant differences were found in the left (p=0.008) 
and right caudate nucleus (p=0.005). These results remained significant even when adding 
MMSE to the model. As shown in Figure 5, these regions significantly correlated with scores on 
the FAB (n= 13) and the TMT-A (n=22). Specifically, partial correlations (TIV, age and MMSE as 
covariates) revealed significant positive associations between FAB scores and the left (r=0.70, 
p=0.03) and right (r=0.68, p=0.03) caudate nucleus, and negative associations between the 
TMT-A and the caudate nucleus, in the left (r=-0.48, p=0.04) and right (r=-0.48, p=0.04) 
hemispheres. Negative correlations, as assessed with the Spearman's rho test, were also 
reported with VH frequency (left caudate, r=-0.46, p=0.03; right caudate, r=-0.46, p=0.03) and 
VH severity (left caudate, r=-0.48, p=0.02; right caudate, r=-0.47, p=0.02). 
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- Insert Figure 5 about here - 
Other differences were detected in the right putamen (p=0.03), left frontal eye field (p=0.03), 
while marginally significant in the right frontal eye field (p=0.05). None survived correction for 
multiple comparisons.  
4.0 Discussion 
The present pilot study provides evidence of the presence of frontal and subcortical GM loss, 
and visual attention deficits in DLB patients with VH compared with those without. Specifically, 
GM atrophy was found in the right superior, middle and medial frontal gyri, and in a 
subcortical cluster comprising the right putamen, caudate nucleus and insula. Interestingly, 
GM volumes in the putamen and caudate were significantly associated with performance on a 
visual attention test, as shown by whole brain correlational analyses. Even though no 
differences were detected between PD subgroups using whole brain VBM, GM loss in the 
caudate nucleus bilaterally was found when restricting the analyses to predefined ROIs, 
suggesting an involvement of this structure also in hallucinating PD patients without dementia. 
To our knowledge, this is the first whole brain VBM study investigating grey and white matter 
volumes, and cognitive impairments associated with VH in LBD that included both samples of 
patients with and without dementia, namely DLB and PD, in comparison with corresponding 
non-hallucinating patients.  
Hallucinating DLB patients presented more severe deficits in visual attention, which remained 
significant even after accounting for visuoperceptive and visuoconstructive abilities. Studies 
have reported attention deficits in patients with both DLB and PD with VH [20,21]. The present 
pilot study adds additional insight about the interaction between attention and visual 
perception deficits in hallucinating patients. Specifically, the attention deficits shown by 
hallucinating DLB patients do not seem to rely on disrupted visual perception. 
Neuropsychological investigations reported evidence of deficits in visual perception in 
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hallucinating patients with LB dementia [18,19], and PD [10,12,15,16]. In the present study, 
however, we found no changes in visuoperceptive/visuoconstructive abilities in DLB and PD 
patients with VH. In spite of this, a non-significant trend indicating worst performance in 
hallucinating DLB was observed in the copy of the Rey figure. Since visuoperceptive and 
visuoconstructive deficits represent disease-specific symptoms of DLB [66], differences 
between VH and NVH patients in these cognitive functions may be subtle, due to the 
pronounced deficits presented also by non-hallucinating patients. We also found significant 
correlations between indices of VH and visual attention (TMT-A) and visuoconstructive 
performance (Rey figure copy), suggesting a contribution of both deficits to VH, as proposed 
by Collerton et al. [9].  
In contrast, PD patients with and without VH presented comparable performance in both 
attention and visuoconstruction. These contrasting results may be due, at least in part, to 
slight differences in the neuropsychological tests used to assess attention and visual 
perception/construction abilities in the two clinical conditions. Some neuropsychological tests 
may be more sensitive than others in detecting such differences, which may be more subtle in 
LBD patients without dementia. Exploratory analyses on other cognitive tests revealed more 
severe executive dysfunction in PD with VH. The cognitive mechanisms underlying VH might be 
slightly different between DLB and PD, especially concerning top-down control mechanisms. 
They may be more related to attention deficits in DLB, and executive dysfunction in PD without 
dementia. Notably, a higher index of neuropsychiatric symptoms, different from VH, was 
observed in PD patients with VH compared to those without, but not in DLB, which may be 
linked to the greater executive dysfunctions observed in PD with hallucinations. In support of 
this view, a recent systematic review reported more severe executive deficits in PD patients 
with neuropsychiatric symptoms, including depression, apathy, impulse control disorders, and 
psychosis [67]. However, when controlling for neuropsychiatric symptoms, FAB scores in PD 
with VH patients were still significantly lower. Executive deficits have been previously 
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associated with VH in PD without dementia by using different neuropsychological tests, such 
as letter fluency, Stroop test, FAB, and go/no-go test [13,68-71].  Indeed, there is a notable 
lack of studies investigating this cognitive aspect in DLB. Executive dysfunction is typically 
observed in PD, regardless of the presence of dementia, and it has been shown to worsen as 
the disease progresses [72,73]. Further research is needed to understand better whether there 
are specific executive domains, and/or top-down attention mechanisms selectively impaired in 
hallucinating LBD patients with and without dementia. In this context, future studies would be 
very informative by including a sample of PDD patients, but also VH/NVH subgroups matched 
for other neuropsychiatric features. This would clarify whether the executive dysfunctions 
observed are related to the occurrence of VH, or represent disorder-specific features (PD vs. 
DLB), maybe exacerbated by the presence of comorbid neuropsychiatric symptoms.  
DLB patients with and without VH presented GM volumetric differences in three big clusters 
located in the right hemisphere, specifically in the superior/middle and medial frontal gyri, and 
subcortical areas, including the putamen, caudate nucleus and insula. All clusters survived a 
cluster-level threshold of p<0.05 corrected for multiple comparisons. Similarly, Sanchez-
Castaneda et al. [28] found GM loss in frontal areas in hallucinating patients with both DLB and 
PDD, which was strongly associated with VH severity in the DLB group. Superior frontal areas 
have been found to be involved in both spatial and object-based attention [74,75], which may 
explain the involvement of frontal regions in the development of VH in DLB. In contrast, frontal 
GM atrophy has not been consistently reported in hallucinating PD patients without dementia. 
Nevertheless, higher LB density in frontal areas, especially in the middle frontal gyrus, has 
been associated with VH in autopsy confirmed PD patients [8,34]. We speculate, therefore, 
that frontal LB accumulation in hallucinating patients may occur earlier in the progression of 
PD, which may result in macrostructural alterations and attention deficits only later, mainly in 
patients with concomitant dementia.  
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In addition to frontal atrophy, DLB patients with VH also showed GM loss in the striatum, both 
in the caudate and putamen. Due to the involvement of the striatum in attention processes 
[36], we propose that its macrostructural alterations may underlie dysfunctional 
pathophysiological mechanisms resulting in attention impairments, and ultimately VH. 
Interestingly, our whole brain correlation analyses showed an association between volumes in 
these regions and scores in a visual attention test, further corroborating this hypothesis.  
No significant results were detected between PD patients with and without VH using whole 
brain VBM. However, when restricting the analyses to predefined ROIs, we observed GM loss 
in subcortical nuclei, especially in the caudate. In turn, regional volumes in the left and right 
caudate significantly correlated with executive dysfunction, attention deficits, and VH severity. 
Disrupted fronto-striatal circuits are among the mechanisms believed to underlie the executive 
dysfunction typical of PD [76,77]. Thus, the striatal atrophy observed in our cohort of PD 
patients may represent a macrostructural hallmark of dysfunctional brain mechanisms 
ultimately resulting in executive and attention deficits, as well as VH.  
Contrary to our hypothesis, no pulvinar GM abnormalities were detected in association with 
VH, neither in PD, nor in DLB, suggesting that the visual attention deficits observed in DLB may 
rely more on other structures of a large-scale attention network, namely frontal and striatal 
areas. No significant differences were found not even in occipito-temporal regions, in contrast 
with other previous studies in PD with VH [25,27]. Reduced glucose metabolism/cerebral 
blood flow have been previously detected in occipito-temporal, occipital, and parietal regions 
in hallucinating LBD patients [22,23,30,31]. Therefore, it may be that occipito-temporal and 
parietal hypometabolism represents a functional hallmark of impaired visual processes 
underpinning VH [24], which may not necessarily result in GM atrophy. 
The subcortical cluster found in the VBM analysis also included a sub-peak in the right insula. It 
has been hypothesised that the insula involvement in discriminating between internally 
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generated and external information may foster the development of hallucinations in 
schizophrenia [78]. Insular reduced GM volume has also been associated with hallucinations in 
other conditions, such as bipolar disorder [79] and AD [80]. The insula, along with the anterior 
cingulate cortex, represents a central hub of the salience network, involved in generating 
appropriate behaviour to salient stimuli by detecting and integrating internal and external 
events [81,82]. Therefore, the GM loss that we observed in the insula may underlie disrupted 
functional networks fostering the development of attention deficits and VH.   
The present pilot study also provided evidence of macrostructural WM alterations in 
hallucinating DLB patients, mainly detected in the genu of the corpus callosum. As the corpus 
callosum interconnects corresponding cortical regions, such as the prefrontal and orbitofrontal 
cortices, it is implicated in different cognitive, sensory and motor functions [83]. Thus, in 
addition to GM abnormalities, corpus callosum alterations may partially contribute to the 
cognitive deficits outlined above.  
A number of limitations should be taken into account when interpreting the results of the 
present study. Firstly, the sample size was reasonably small, and for this reason this can only 
be seen as a reference pilot study for future work. Future studies with larger sample sizes may 
elucidate further the role of specific cognitive functions and GM abnormalities linked to VH in 
LBD. Moreover, some clinical and neuropsychological data were not available, due to the 
retrospective nature of the study. Thus, analyses on cognitive measures included slightly 
different sample sizes, depending on the variables taken into account. Furthermore, cognitive 
results obtained for the DLB and PD groups were not fully comparable, due to differences in 
the neuropsychological testing. The tests used were not specifically designed to assess 
cognitive deficits related to VH. However, these tests are widely used in clinical settings, 
suggesting that the results from the present study may be, in the future, more easily 
transferable to clinical practice. Another limitation concerns the NPI, which is not specific for 
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the assessment of VH in LBD. Therefore, other tools may be more sensitive in detecting 
phenomenological characteristics that may clarify some of the differences detected between 
conditions.  
5.0 Conclusion 
The present study adds further knowledge about the presence of structural brain 
abnormalities, and cognitive deficits in LBD patients with VH, and the differences and 
similarities between clinical conditions experiencing this neuropsychiatric symptom. Our 
findings suggest that attention deficits, and their neural substrates, may play a significant role 
in the development of VH, in line with integrative models of VH. [9,84]. Specifically, Collerton 
et al. [9] proposed that VH might be the result of the combination of attentional and 
perceptual deficits. Our findings confirm the model only in part. Indeed, we found that DLB 
patients with VH had more severe deficits in visual attention, compared to patients without, 
which seemed to be independent from deficits in visual perception/construction. In turn, 
visuoconstructive deficits correlated with VH indices, but no between-group differences were 
detected. We suggest, therefore, that top-down attention mechanisms might have a 
predominant role in the development of VH, especially in patients with dementia. This is 
consistent with the pattern of GM atrophy we found in these patients, given the important 
role played by a network of fronto-parietal regions and the striatum in the top-down control of 
attention [35,36].  
On the other hand, GM atrophy was identified in the striatum in PD without dementia only 
when restricting the analyses to predefined ROIs. We speculate that prefrontal 
macrostructural alterations might be more pronounced in hallucinating LBD patients with 
dementia. Cognitive changes, instead, may be detectable also in cognitively normal PD, and 
may be a behavioural hallmark of more severely disrupted fronto-striatal circuits. However, 
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the relationship between attention and executive deficits in PD, and their role in the 
development of VH still needs further clarification.  
The presence of VH has a significant impact on the quality of life of patients and their 
caregivers, and they have been found to be a strong predictor of institutionalisation in PD 
[6,85]. However, there is currently no treatment specifically targeted to VH. Neuroimaging 
methods, and neuropsychological measures represent valuable tools that might provide a 
better understanding of the neural substrates, and cognitive deficits associated with the 
development of VH in LBD. In this context, the detection of symptom-specific biomarkers, and 
a wider knowledge of the underlying pathophysiology, may be helpful in the development of 
new targets to be used in the assessment of treatments efficacy in clinical trials.  
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Figure captions 
Figure 1. Significantly lower scores in the digit cancellation in DLB VH compared with NVH. ** 
p<0.01. 
Figure 2. Regions of reduced GM volume in DLB patients with VH compared to those without: 
A) right medial orbitofrontal cortex, superior frontal, middle frontal and rectus gyri, and B) 
right putamen, insula and caudate nucleus; C) right gyrus rectus. The colour bar indicates the z 
scores with the cluster-level threshold of p<0.05 FWE corrected for multiple comparisons, with 
TIV and age as covariates of no interest. Images are shown in neurological orientation, i.e. L/L, 
R/R. 
Figure 3. Results from whole brain voxel-based positive correlation between grey matter 
volumes and A) digit cancellation and B) VOSP silhouettes scores. The colour bar indicates the 
z scores with the cluster-level threshold of p<0.05 FWE corrected for multiple comparisons 
with TIV and age as covariates of no interest. Images are shown in neurological orientation, i.e. 
L/L, R/R. 
Figure 4. A) Subcortical ROI of decreased grey matter volume as resulted from VBM analysis 
(ROI regions: right putamen, insula and caudate). B) Scatterplot showing the significant 
correlation between the digit cancellation test scores and the ROI volumes (MRI signal). 
Figure 5. Top) ROIs: left (in red) and right (in blue) caudate nucleus. Bottom) Scatterplots 
showing the significant correlation between the ROIs volumes (MRI signal) and the FAB and 
TMT-A (seconds) scores. 
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Table 1. Demographic, clinical and volumetric characteristics of DLB patients with and 
without VH. Mean and SD values are reported for each variable unless otherwise 
specified. 
Characteristic DLB VH (n=11)  DLB NVH (n=17)  p value 
Demographics  
   
Age 75.09 (5.03) 73.65 (6.47) 0.54 a 
Gender M:F 4:7 9:8 0.46 b 
Years of education 6.09 (3.24) 8 (4.90) 0.30 c 
Clinical features     
Disease duration (years) 2.64 (1.21) 2.06 (1.30) 0.17 c 
MMSE 22.45 (3.45) 25.00 (3.50) 0.07 a 
UPDRS III 8.00 (11.86) 4.59 (5.92) 0.83 c  
RBD d 91% 47% 0.04 b  
Cognitive fluctuation 73% 88% 0.35 b  
NPI total score 15.82 (9.64) 5.53 (3.7) <0.01 c  
NPI tot minus NPI hallucination  11.64 (9.51) 5.53 (3.71) 0.17 c 
Brain volumes (ml)    
Total GM volume 479.20 (51.83) 493.39 (30.86) 0.37 c 
Total WM volume 441.79 (65.81) 447.31 (59.50) 0.82 c 
Total CSF volume 525.06 (81.66) 479.73 (82.30) 0.17 c 
Total intracranial volume 1446.04 (134.09) 1420.43 (140.75) 0.64 c 
CSF: cerebrospinal fluid; DLB: dementia with Lewy bodies; F: female; GM: grey matter; M: male; MMSE: Mini-
Mental State Examination; NPI: neuropsychiatric inventory; NVH: no visual hallucinations; RBD: REM sleep 
behaviour disorder; SD: standard deviation; UPDRS: Unified Parkinson¶V'LVHDVH5DWLQJ6FDOH9+YLVXDO
hallucinations; WM: white matter. a Independent-sample t-test; b )LVKHU¶V([DFW7HVWc Mann-Whitney U test; d 
Missing data for a VH patient.  
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Table 2. Demographic, clinical and volumetric characteristics of PD patients with and 
without VH. Mean and SD values are reported for each variable unless otherwise 
specified. 
Characteristic PD VH (n=9)  PD NVH (n=15)  Controls (n=15) p value 
Demographics 
    
Age 67.00 (10.56) 67.33 (8.05) 67.27 (8.99) 1.00 a 
Gender M:F 5:4 10:5 10:5 0.83 b 
Years of education 11.33 (5.27) 11.33 (4.24) 11.47 (4.21) 0.97 c 
Clinical features     
Disease duration (years) 9.89 (5.68) 10 (4.23) ± 0.76 d 
MMSE 26.22 (2.05) 27.60 (1.68) 29.27 (0.88) 0.001 c 
H&Y f 2 (1.00) 2.29 (0.95) ± 0.60 d 
LED mg/d 608.33 (247.18) 546.27 (204.35) ± 0.51 e 
Sleep disturbances  89% 67% ± 0.22 b 
NPI total score 32.67 (25.45) 9.00 (9.89) ± 0.01 d 
NPI tot minus NPI hallucination 28.00 (24.60) 9.00 (9.89) ± 0.03 d 
Brain volumes (ml)     
Total GM volume 561.69 (71.52) 613.79 (64.86) 604.25 (59.94) 0.16 a 
Total WM volume 458.48 (58.26) 498.09 (64.64) 460.21 (49.37) 0.14 a 
Total CSF volume 393.29 (93.24) 376.86 (87.48) 378.03 (86.31) 0.89 a 
Total intracranial volume 1413.46 (159.90) 1488.74 (146.13) 1442.48 (105.78) 0.40 a 
CSF: cerebrospinal fluid; F: female; GM: grey matter; H&Y: Hoehn and Yahr scale; LED: Levodopa equivalent 
dose; M: male; MMSE: Mini-Mental State Examination; NPI: neuropsychiatric inventory; NVH: no visual 
KDOOXFLQDWLRQV3'3DUNLQVRQ¶VGLsease; SD: standard deviation; VH: visual hallucinations; WM: white matter. a One-
way ANOVA; b Pearson Chi-Square; c Kruskal-Wallis Test; d Mann-Whitney Test; e Independent-sample t-test; f 
Missing data for 4 VH patients and 8 without VH. 
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Table 3. Differences in neuropsychological tests assessing visual attention and visual 
perception/visuoconstruction between DLB patients with and without VH. 
Test 
DLB VH DLB NVH 
p value 
n Mean (SD) Median (IQR) n Mean (SD) Median (IQR) 
Digit cancellation 10 24.40 (8.90) 25.00 (12.00) 16 34.81 (9.90) 37.50 (16.00) 0.01 a 
TMT-A (seconds) 8 184.00 (94.00) 139.50 (152) 14 123.64 (73.04) 96.50 (61.00) 0.05 b 
Rey figure copy 9 11.94 (15.04) 2.00 (28.5) 14 20.68 (10.86) 22.00 (19.13) 0.16 b 
VOSP Silhouettes 11 9.45 (5.37) 10.00 (7.00) 16 12.44 (3.76) 13.00 (5.25) 0.10 a 
DLB: dementia with Lewy bodies; IQR: interquartile range; NVH: no visual hallucinations; SD: standard deviation; 
TMT-A: Trial Making Test A; VH: visual hallucinations; VOSP: Visual and Object Space Perception battery. a 
Independent-sample t-test; b Independent-sample Mann-Whitney U test. 
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Table 4. Differences in neuropsychological tests assessing visual attention and 
visuoconstruction between PD patients with and without VH. 
Test 
PD VH PD NVH 
p value 
n Mean (SD) Median (IQR) n Mean (SD) Median (IQR) 
TMT-A (seconds) 7 71.43 (23.75) 64.00 (38.00) 15 61.20 (31.01) 58.00 (39) 0.45 a 
Rey figure copy 8 28.06 (2.47) 28.50 (4.30) 14 27.86 (7.15) 29.00 (12.90) 0.92 a 
IQR: interquartile range; NVH: no visuDOKDOOXFLQDWLRQV3'3DUNLQVRQ¶VGLVHDVH6'VWDQGDUGGHYLDWLRQ707-A: 
Trial Making Test A; VH: visual hallucinations. a Independent-sample t-test. 
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Table 5. Regions of reduced GM and WM volume in DLB patients with VH compared 
to NVH, and whole brain voxel-based correlations between GM volumes and digit 
cancellation and VOSP silhouette. 
Structure Side Cluster 
size  MNI coordinates T score Z score p value 
a
 
GM loss in DLB patients with VH 
Superior Frontal Gyrus (BA 10) R 1328 9 62 -12 6.28 4.79 <0.001 
Superior Frontal Gyrus (BA 10) R  21 62 4 5.41 4.33  
Middle Frontal Gyrus R  34 54 -9 5.06 4.14  
Putamen R 625 26 20 -4 5.50 4.38 0.02 
Insula (BA 13) R  38 26 4 4.44 3.76  
Caudate Head R  14 20 -2 3.83 3.35  
Medial Frontal Gyrus (BA 11) R 576 3 45 -27 4.57 3.84 0.03 
Medial Frontal Gyrus (BA 11) R  6 32 -26 4.44 3.76  
WM loss in DLB patients with VH 
Forceps minor / Genu of corpus 
callosum 
R 1043 9 30 0 4.55 3.83 <0.001 
Body of corpus callosum R  16 15 24 4.38 3.72  
Right Anterior thalamic radiation / 
Genu of corpus callosum 
R  20 24 21 4.36 3.71  
GM volumes and digit cancellation positive correlation  
Putamen R 599 22 14 3 5.59 4.37 0.02 
Caudate Body R  15 -3 20 4.51 3.76  
Caudate Body R  18 -12 21 4.32 3.63  
Caudate Body L 482 -15 -4 24 5.47 4.30 0.05 
Caudate Body L  -20 10 18 5.18 4.14  
Caudate Body L  -9 -2 14 3.67 3.21  
GM volumes and VOSP silhouettes positive correlation  
Inferior Temporal Gyrus (BA 20) R 1059 60 -36 -20 5.32 4.25 0.002 
Middle Temporal Gyrus (BA 21) R  66 -28 -14 5.29 4.23  
Middle Temporal Gyrus (BA 21) R  64 -22 -20 4.87 4.00  
BA: Brodmann area; DLB: dementia with Lewy bodies; FWE: family-wise error; GM: grey matter; NVH: no VH; 
TIV: total intracranial volume; VH: visual hallucinations; WM: white matter. a Cluster-level threshold of p<0.05 
FWE corrected for multiple comparisons with TIV and age as covariates of no interest. 
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Figure 2 
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Figure 3 
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Figure 4 
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Supplementary materials  
Table S1. Differences in screening neuropsychological tests between DLB patients with 
and without VH. 
Test 
DLB VH DLB NVH 
p value 
n Mean (SD) Median (IQR) n Mean (SD) Median (IQR) 
Digit span:       
 
Forward 10 3.70 (1.57) 4.0 (1.25) 16 4.75 (1.06) 4.50 (1.75) 0.07 b 
Backward 9 2.00 (0.82) 2.0 (0.25) 15 2.81 (1.17) 3.00 (1.75) 0.04 b 
Prose memory:       
 
Immediate recall 11 7.36 (5.57) 6.0 (5.00) 17 7.24 (3.98) 6.00 (3.50) 0.87 b 
Delayed recall 11 8.09 (4.97) 7.0 (7.00) 17 7.94 (5.06) 7.00 (6.50) 0.89 b 
Phonemic fluency 10 14.5 (10.5) 11.50 (8.50) 14 17.07 (11.6) 14.0 (19.25) 0.84 b 
Clock drawing 10 3.80 (3.22) 4.0 (5.50) 17 4.80 (3.46) 6.00 (6.25) 0.47 a 
Rey figure recall 9 2.94 (4.35) 0.0 (6.25) 14 8.00 (5.97) 7.75 (10.00) 0.03 b  
VOSP:       
 
Screening test 11 18.73 (2.2) 20.0 (1.0) 16 19.38 (0.72) 19.50 (1.00) 0.96 b 
Incomplete letters 11 9.27 (6.25) 8.0 (10.0) 16 12.38 (7.32) 15.0 (12.25) 0.24 b 
Object decision 11 8.90 (4.97) 11.0 (7.0) 15 11.07 (3.82) 12.00 (6.00) 0.28 b 
Progressive 
silhouettes 11 9.55 (6.88) 13.0 (16.0) 15 11.60 (3.85) 11.00 (4.00) 0.74 
b
 
Dot counting 11 8.45 (2.30) 9.0 (2.0) 16 9.44 (1.50) 10.00 (0.75) 0.10 b 
Position 
discrimination 11 15.18 (7.4) 19.0 (5.0) 16 17.44 (3.67) 19.50 (6.75) 0.37 
b
 
Number location 11 6.09 (4.25) 7.0 (7.0) 16 6.06 (2.46) 7.00 (4.00) 0.98 a 
Cube analysis 11 4.09 (3.08) 5.0 (6.0) 16 5.69 (3.24) 5.00 (5.50) 0.21 a 
DLB: dementia with Lewy bodies; IQR: interquartile range; NVH: no visual hallucinations; SD: standard deviation; 
VH: visual hallucinations; VOSP: Visual and Object Space Perception battery. a Independent-sample t-test; b 
Independent-sample Mann-Whitney U test. 
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Table S2. Differences in screening neuropsychological tests between PD patients with 
and without VH. 
Test 
PD VH PD NVH 
p value 
n Mean (SD) Median (IQR) n Mean (SD) Median (IQR) 
Digit span:       
 
Forward 5 6.00 (1.23) 6.0 (2.0) 8 6.38 (0.92) 6.0 (1.0) 0.54 a 
Backward 5 3.60 (0.89) 3.0 (2.0) 8 3.63 (0.74) 3.50 (1.0) 0.87 b 
RAVLT       
 
Immediate recall 6 26.33 (6.47) 26.0 (11.0) 11 38.73 (11.33) 34.0 (21.0) 0.03 a 
Delayed recall 6 5.17 (2.32) 5.50 (5.0) 11 7.73 (3.50) 9.0 (7.0) 0.17 b 
Phonemic fluency 8 24.25 (4.92) 25.0 (8.0) 15 31.6 (9.47) 31.0 (16.0) 0.05 a 
Rey figure recall 8 11.31 (4.87) 12.25 (9.10) 14 12.73 (5.85) 13.50 (5.30) 0.57 a 
Stroop test (s) 6 64.67 (77.5) 36.50 (56.0) 15 32.83 (17.82) 28.50 (29.0) 0.48 b 
Stroop test (errors) 6 5.00 (5.97) 3.0 (6.0) 15 3.30 (5.11) 2.0 (5.0) 0.31 b 
FAB 6 11.83 (2.40) 12.0 (3.0)  7 16.14 (1.57) 17.0 (2.0) 0.01 b 
FAB: Frontal Assessment Battery; IQR: interquartile range; RAVLT: Rey Auditory Verbal Learning Test; NVH: no 
YLVXDOKDOOXFLQDWLRQV3'3DUNLQVRQ¶VGLVHDVHVVHFRQGV6'VWDQGDUGGHYLDWLRQ9+YLVXDOKDOOXFLQDWLRQVa 
Independent-sample t-test; b Independent-sample Mann-Whitney U test. 
 
 
 
 
 
 
 
 
